That not correct. They helping them to get licence in Australia...

That not correct.
They helping them to get licence in Australia as Novavax has not presence in Australia and also helping with rollout .
IDT is planning to manufacture the vaccine.

The Therapeutic Goods Administration last week granted "provisional determination" to Novavax for the vaccine, paving the way for the company to start applying to register the product in Australia.

Novavax does not have a presence in the Asia Pacific region and has chosen Biocelect, a small private pharmaceuticals commercialisation firm based in Macquarie Street, Sydney, to be the vaccine's sponsor.

The company, which was founded in 2014 and has just 22 staff, will assist Novavax in providing data to the Australian regulator ahead of approval, as well as helping plan for delivery and rollout of doses across the country.

Biocelect chief executive Karl Herz, a local pharmaceuticals industry veteran who has more than two decades of experience with companies including Sigma Pharmaceuticals, Sanofi and GSK, said his company was "extremely pleased" to be chosen to work with Novavax."As we await the data from Novavax’s phase III clinical trials, we are very hopeful the Novavax vaccine candidate will be approved by regulatory authorities and play a significant role in protecting the Australian and New Zealand populations against COVID-19," Mr Herz said.Over the past 12 months vaccine industry experts have argued smaller firms like Biocelect have specialised knowledge that will be critical to the vaccine rollout. Novavax executive vice president John Trizzino said the company had reached an "important milestone" in gaining a provisional determination from the TGA and was glad to be able to work with Biocelect. The two firms have previously worked together on other Novavax research projects.